<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute lymphoblastic leukemia/lymphoblastic lymphoma: Outcomes and late effects of treatment in children and adolescents</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute lymphoblastic leukemia/lymphoblastic lymphoma: Outcomes and late effects of treatment in children and adolescents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute lymphoblastic leukemia/lymphoblastic lymphoma: Outcomes and late effects of treatment in children and adolescents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Terzah M Horton, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer L McNeer, MD, MS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Julie R Park, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter Newburger, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) is the most common malignancy in children, accounting for one-quarter of all pediatric cancer diagnoses. ALL/LBL refers to malignancies of undifferentiated lymphoid precursors that involve bone marrow, blood, and/or extramedullary sites. There is a large body of literature that considers ALL and LBL the same entity, distinguished only by the primary location of the disease. </p><p>ALL/LBL is categorized according to immunophenotype as:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>T cell (T lymphoblastic) ALL/LBL</strong></p><p class="bulletIndent1"><span class="glyph">●</span><strong>B cell (B lymphoblastic or B precursor) ALL/LBL</strong> </p><p></p><p class="bulletIndent1">In addition, there are distinct subtypes of B cell ALL/LBL, which are defined by molecular features such as Philadelphia chromosome (Ph)-positive ALL/LBL and Ph-like ALL/LBL. </p><p></p><p>Leukemia with features of B cells or T cells plus myeloid characteristics is described as mixed phenotype acute leukemia, which is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/116801.html" rel="external">"Mixed phenotype acute leukemia"</a>.)</p><p>Outcomes and late effects of treatment of ALL/LBL in children are reviewed in this topic. </p><p>Clinical presentation, classification, risk group stratification, and treatment of childhood ALL are discussed separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6244.html" rel="external">"Overview of the clinical presentation and diagnosis of acute lymphoblastic leukemia/lymphoma in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6248.html" rel="external">"Prognostic factors and risk group stratification for acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents"</a>.)</p><p></p><p>ALL/LBL in the setting of Down syndrome/trisomy 21 or various inherited conditions may require distinctive treatment, experience specific toxicities, and have different prognoses compared with ALL/LBL in children without these underlying conditions. ALL/LBL in these settings are discussed separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2917.html" rel="external">"Down syndrome: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/93183.html" rel="external">"Familial disorders of acute leukemia and myelodysplastic syndromes"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">OUTCOMES</span></p><p class="headingAnchor" id="H29268309"><span class="h2">Survival</span><span class="headingEndMark"> — </span>Survival for children with ALL/LBL has steadily improved since the 1980s, with an increasing proportion of children who are cured [<a href="#rid1">1-5</a>]. Treatment outcomes are influenced by the disease category (eg, B cell, T cell), clinical risk factors (eg, age, extranodal involvement), and genetic features (chromosomal and molecular abnormalities). </p><p>Children with ALL/LBL in developed nations have approximately 90 percent five-year overall survival (OS) and event-free survival (EFS); the 10-year OS in this setting is estimated to be 85 to 88 percent [<a href="#rid2">2,6-9</a>]. Treatment for pediatric ALL/LBL is stratified, so that higher-risk disease is treated with more aggressive therapy, while lower-risk disease is treated with less intensive therapy to reduce toxicity while maintaining favorable outcomes. Among other advances, standardized treatment at specialized centers and routine prophylaxis to prevent relapse in the central nervous system (CNS) and other extranodal sites have contributed to improved outcomes. </p><p>By contrast, the rate of cure is &lt;35 percent for children in the developing world, in part because of abandonment of treatment and/or lack of dedicated, multidisciplinary pediatric oncology units [<a href="#rid10">10-13</a>]. When children in the developing world were treated on international protocols, five-year rates of OS and EFS improved (82 and 74 percent, respectively), yet treatment-related mortality (TRM) remained elevated (eg, 5 percent death in complete remission [CR]) [<a href="#rid14">14,15</a>]. TRM correlates with differences in available supportive care [<a href="#rid16">16</a>].</p><p>Clinical characteristics (eg, age) and pathologic features of the leukemic blasts (eg, immunophenotype, genetic findings) contribute importantly to outcomes in pediatric ALL/LBL.</p><p class="headingAnchor" id="H1376036624"><span class="h3">Effect of age</span><span class="headingEndMark"> — </span>Survival is related to the age at diagnosis, with adolescents and young adults (AYAs) faring less well than younger children, while ALL/LBL in infants has a grim prognosis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adolescents and young adults</strong> <strong>ALL/LBL</strong> – Survival in AYAs is influenced by a lower percentage of cases with favorable cytogenetics (eg, <em>ETV6::RUNX1</em>) and a concurrent increase in adverse-risk cytogenetics (eg, <em>BCR::ABL1</em>, hypodiploidy) [<a href="#rid17">17</a>]. While prognosis is improving with the development of AYA protocols, OS at 20 years is approximately 48 percent. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infant ALL/LBL</strong> – The prognosis for infant ALL/LBL is poor, with an EFS of 10 to 30 percent [<a href="#rid18">18-20</a>]. </p><p></p><p class="bulletIndent1">Infants tend to have higher white blood cell (WBC) counts at presentation<em>, KMT2A</em> (formerly called <em>MLL</em>) translocations, and skin involvement [<a href="#rid21">21</a>]. Aggressive treatment protocols are associated with improved outcomes in some studies [<a href="#rid22">22-25</a>]. The outcome for infants &lt;90 days at diagnosis who have the t(4;11)<em> KMT2A</em> translocation with a high WBC count was substantially worse than for older infants without this translocation [<a href="#rid26">26,27</a>]. Treatment intensity is often decreased for infants &lt;90 days of age, since this group is very sensitive to adverse effects of chemotherapy [<a href="#rid28">28</a>]. </p><p></p><p class="headingAnchor" id="H1921290189"><span class="h3">Classification</span><span class="headingEndMark"> — </span>Diagnosis, treatment stratification, and prognosis varies according to the ALL/LBL disease category.</p><p>ALL/LBL should be classified using either the International Consensus Classification [<a href="#rid29">29</a>] or the 5<sup>th</sup> edition of the World Health Organization classification of lymphoid neoplasms [<a href="#rid30">30</a>]. Both systems use cytogenetic and molecular features to classify ALL/LBL, and the use of either is acceptable. </p><p>Classification of ALL/LBL is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms", section on 'Lymphoid neoplasms'</a>.)</p><p class="headingAnchor" id="H2848819651"><span class="h4">B cell ALL/LBL</span><span class="headingEndMark"> — </span>B cell ALL/LBL (B precursor ALL/LBL) is the largest category of ALL/LBL, and it includes many genetic subtypes that are distinguished by chromosomal abnormalities (eg, aneuploidy or translocations), which deregulate hematopoietic transcription factors, epigenetic modifiers, cytokine receptors, or tyrosine kinases [<a href="#rid31">31-33</a>]. </p><p>Outcomes are strongly associated with genetic features, clinical characteristics (eg, age, WBC count at presentation), response to induction therapy, and persistence of measurable residual disease (MRD) at specified time points during treatment. Details of prognostic features and risk group stratification are presented separately. (See  <a class="medical medical_review" href="/z/d/html/6248.html" rel="external">"Prognostic factors and risk group stratification for acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents"</a>.)</p><p>Following are examples of outcomes stratified according to the B cell ALL/LBL risk group:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low or standard risk</strong> – For children with low- or standard-risk B cell ALL/LBL, five-year EFS is &gt;90 percent in children who have a good response to induction chemotherapy [<a href="#rid6">6,34-41</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High risk</strong> – For patients with high-risk features at presentation and a good early response to induction chemotherapy, five-year EFS with intensive chemotherapy is &gt;80 percent [<a href="#rid34">34-40,42</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Very high risk</strong> – For children with hypodiploid karyotype (&lt;44 chromosomes) or a slow response to early phases of chemotherapy, five-year EFS is &lt;60 percent [<a href="#rid42">42-49</a>].</p><p></p><p>Management of B cell ALL/LBL is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents"</a>.)</p><p class="headingAnchor" id="H2893673359"><span class="h4">T cell ALL/LBL</span><span class="headingEndMark"> — </span>T cell ALL/LBL represents approximately 15 percent of pediatric ALL/LBL [<a href="#rid31">31-33</a>]. It arises from a multistep process of accumulated mutations that alter growth, differentiation, proliferation, and cell survival during thymopoiesis. The genetics of T cell ALL/LBL are highly heterogeneous, and chromosomal abnormalities are found in almost all patients; altered expression of T lineage transcription factors, NOTCH1/MYC signaling, and cell-cycle control are affected in most cases of T cell ALL/LBL. Despite the numerous mutations associated with T cell ALL, most do not contribute to risk stratification. T cell ALL/LBL has a higher incidence in males than in females and in patients with African ancestry; high WBC count and a mediastinal mass at presentation are more common in this subtype of ALL/LBL [<a href="#rid50">50,51</a>]. </p><p>Although most children with T cell ALL/LBL have high-risk features at presentation (eg, unfavorable age or high WBC count), outcomes now rival those with B-precursor ALL/LBL [<a href="#rid52">52,53</a>]. The COG AALL0434 trial of T cell ALL/LBL reported 84 percent five-year EFS; this trial compared two different methods of <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">methotrexate</a> delivery during the interim maintenance phase and also randomized patients to add <a class="drug drug_pediatric" data-topicid="12993" href="/z/d/drug information/12993.html" rel="external">nelarabine</a> or not [<a href="#rid54">54,55</a>]. Outcomes for the AALL1231 clinical trial, which decreased radiation for almost all patients, were similar [<a href="#rid55">55</a>].</p><p>Management of T cell ALL/LBL is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents", section on 'T cell ALL/LBL'</a>.)</p><p class="headingAnchor" id="H3322297120"><span class="h4">Philadelphia chromosome positive/<i>BCR::ABL1</i> positive</span><span class="headingEndMark"> — </span><em>BCR::ABL1</em> positive ALL/LBL accounts for approximately 2 to 3 percent of pediatric ALL/LBL [<a href="#rid56">56</a>]. It was associated with a dismal prognosis until the routine incorporation of a tyrosine kinase inhibitor (TKI) into multiagent chemotherapy regimens. </p><p>Among 91 children with Philadelphia chromosome-positive (Ph+) ALL/LBL treated with <a class="drug drug_pediatric" data-topicid="12618" href="/z/d/drug information/12618.html" rel="external">imatinib</a> plus intensive chemotherapy in Children’s Oncology Group (COG) trial AALL0031, five-year EFS was 70 percent [<a href="#rid57">57</a>]. Treatment that included the second generation TKI, <a class="drug drug_pediatric" data-topicid="120511" href="/z/d/drug information/120511.html" rel="external">dasatinib</a>, achieved similar or better outcomes compared with imatinib [<a href="#rid58">58,59</a>]. </p><p>Management of <em>BCR::ABL1</em> positive ALL/LBL is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents", section on 'Ph+ B-ALL/LBL'</a>.)</p><p class="headingAnchor" id="H972407771"><span class="h4">Philadelphia chromosome-like ALL/LBL</span><span class="headingEndMark"> — </span>Ph-like ALL/LBL is a disease subtype that has a pattern of gene expression similar to Ph+ ALL/LBL, but the<em> BCR::ABL1</em> fusion gene is not detected [<a href="#rid32">32,60,61</a>]. The genetics are heterogeneous, but most cases involve activating mutations of <em>CRLF2</em>/Janus kinase (JAK) pathway signaling, <em>ABL1</em>-class tyrosine kinase fusions, or alterations of other kinases or signaling molecules. </p><p>The incidence of pediatric Ph-like ALL/LBL increases with age, from 10 percent in younger children to 25 to 30 percent in AYAs [<a href="#rid62">62</a>]; it is also more common in males and individuals of Hispanic ancestry [<a href="#rid63">63</a>]. In one report, OS was approximately 40 percent, and clinical outcomes correlated inversely with age [<a href="#rid64">64</a>].</p><p>Treatment of Ph-like ALL/LBL with TKIs and JAK inhibitors (eg, <a class="drug drug_pediatric" data-topicid="122146" href="/z/d/drug information/122146.html" rel="external">ruxolitinib</a>) is being evaluated. (See  <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents"</a>.)</p><p class="headingAnchor" id="H1348215573"><span class="h2">Relapse</span><span class="headingEndMark"> — </span>Most relapses of ALL/LBL in children occur within the first year after completing therapy. Certain clinical and pathologic features are associated with increased risk for relapse.</p><p>The risk of relapse is highest in the first year and decreases by 7 to 10 percent per year in the second through fourth years after treatment cessation [<a href="#rid65">65</a>]; recurrences after four years are rare [<a href="#rid66">66,67</a>]. For children who experienced 10 years of EFS after achieving CR, the 30-year risk for leukemic relapse was 0.6 percent [<a href="#rid68">68</a>]. For children who did not receive radiation therapy, the 30-year OS was 98.3 percent, which was comparable to that of the general United States population matched for age, sex, and race.</p><p>Clinical, biological, and response-based features are associated with relapse in childhood ALL/LBL [<a href="#rid69">69</a>]. Persistence of MRD after induction chemotherapy is the strongest predictor of relapse, but one-half of relapses occur in patients with an excellent response to therapy during induction [<a href="#rid69">69</a>]. Other factors associated with increased risk for relapse are age &lt;1 year or ≥10 years, CNS involvement, elevated WBC at diagnosis, and pathologic features, such as T cell immunophenotype, hypodiploid karyotype (&lt;44 chromosomes), and molecular features (eg, Ph-like subtype, iAMP21, mutated <em>IKZF1</em> or <em>KMT2A</em>). </p><p class="headingAnchor" id="H3"><span class="h2">Treatment-related mortality</span><span class="headingEndMark"> — </span>Despite improvements in long-term survival, children with ALL/LBL remain at risk for late toxicity and TRM. Most TRM occurs in the first year of ALL/LBL treatment (ie, during induction therapy or shortly thereafter). </p><p>Many factors contribute to TRM, including the aggressiveness of the treatment protocol and adverse events associated with high-dose corticosteroids, antibiotics, chemotherapy, and hematopoietic cell transplantation. Estimates of overall TRM (ie, deaths during induction or while in CR) range from 2.6 to 5 percent [<a href="#rid70">70-73</a>]. As an example, in a study of 1652 children with ALL/LBL (1992 through 2001), TRM during induction phase of therapy was 1.2 percent, and TRM while in first CR was 2.2 percent; infection was the most frequent cause of death during induction (68 percent) [<a href="#rid73">73</a>]. </p><p>Long-term survival with pediatric ALL/LBL approaches 90 percent, and late mortality due to relapse, long-term toxicities, and second cancers has decreased among survivors of childhood leukemia [<a href="#rid74">74</a>]. The Childhood Cancer Survivor Study (CCSS) evaluated late mortality from 1970 through 1999 among 8500 patients who survived ≥5 years after diagnosis of childhood ALL/LBL [<a href="#rid75">75</a>]; mortality in the 25 years after completing treatment was 18 percent in earlier decades of the study but declined to 6 percent by 1990.</p><p>Children with Down syndrome are at an increased risk for treatment-related complications and TRM, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/139448.html" rel="external">"Myeloid leukemia associated with Down syndrome (ML-DS)"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">LATE EFFECTS</span><span class="headingEndMark"> — </span>Long-term survivors of pediatric ALL/LBL may experience late adverse effects (AEs) of treatment. The incidence of specific complications is influenced by the type and intensity of treatment and age. </p><p>Prominent late AEs associated with treatment of ALL/LBL in children include neurocognitive dysfunction and other central nervous system (CNS) complications, endocrinopathies, cardiotoxicity, infections, and second cancers; other late effects include decreased linear growth, depression, fatigue, and anxiety [<a href="#rid76">76-80</a>]. </p><p>By age 35 years, the cumulative burden of late effects of cancer treatment was higher for leukemias than for treatment of lymphomas or solid tumors [<a href="#rid81">81</a>]. The greatest burden of late effects of chemotherapy and/or radiation therapy (RT) by age 45 years involved cardiovascular conditions, followed by endocrine, gastrointestinal, hematologic, and immunologic/infectious complications. </p><p>The likelihood of specific complications is influenced by the age at treatment and the type and intensity of therapy. As examples, neurocognitive decline is more likely to occur in children treated with RT at &lt;6 years [<a href="#rid82">82</a>], while impaired fertility is more common in adolescents who received <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">cyclophosphamide</a> or other alkylating agents [<a href="#rid83">83</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Neurologic effects</span></p><p class="headingAnchor" id="H9"><span class="h3">Central nervous system, mental health, and cognition</span><span class="headingEndMark"> — </span>Late neurologic AEs vary with the method and intensity of CNS prophylaxis/treatment.</p><p>Effects of CNS prophylaxis and treatment on neurologic development are variable [<a href="#rid84">84,85</a>]. Impaired cognitive function has been reported in children treated for ALL/LBL, particularly in those who received cranial RT or triple intrathecal (IT) chemotherapy [<a href="#rid82">82,86-90</a>]. </p><p>Contemporary treatment protocols have reduced or eliminated cranial RT as CNS prophylaxis for most children with ALL/LBL to minimize the incidence and severity of cognitive impairment [<a href="#rid91">91-93</a>]. Treatment protocols now use substantially lower RT doses (eg, 12 to 18 grey [Gy]) compared with earlier treatments; this appears to have decreased, but not eliminated, the incidence and severity of cognitive impairment [<a href="#rid88">88,94-96</a>]. (See  <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents", section on 'CNS management'</a>.)</p><p>CNS management in children with ALL/LBL is associated with various neurologic effects, including attention disorders, late cognitive deficits, and mental health symptoms. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic impairment</strong> – Neurologic sequelae vary with inclusion of RT in prophylaxis and treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Radiation therapy administered</strong> – Younger children (eg, &lt;6 years) who received high-dose cranial RT (≥24 Gy) in combination with IT chemotherapy are at the greatest risk for subsequent CNS impairment [<a href="#rid97">97</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A study of 150 survivors of childhood ALL/LBL (35 of whom had received cranial RT) reported that, with a 10-year median follow-up, 83 percent had minimal or no impairment, 14 percent had moderate deficiencies, and 3 percent had severe cognitive dysfunction, as evaluated with standardized neuropsychologic tests (age-adapted versions of the Wechsler test) [<a href="#rid86">86</a>]. However, median intelligence quotient (IQ) scores for the ALL/LBL survivors were comparable to those in the general population. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In another study, 22 patients with ALL/LBL were treated with chemotherapy alone (including high-dose <a class="drug drug_pediatric" data-topicid="12595" href="/z/d/drug information/12595.html" rel="external">methotrexate</a>), and 11 were treated with RT plus chemotherapy. Those treated with RT had significant cognitive effects compared with normal controls [<a href="#rid98">98</a>]. Children treated with either chemotherapy alone or chemotherapy plus 12 Gy RT had decreased long-term memory, recall, and processing speed, along with abnormalities of the hippocampus and caudate nucleus by magnetic resonance imaging (MRI). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Compared with matched controls, children who received cranial RT at an early age had inferior ninth-grade school grade reports in all school subjects [<a href="#rid99">99</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>No radiation therapy administered</strong> – A meta-analysis of 10 studies reported neurologic impairment in 509 pediatric ALL/LBL survivors in continuous first complete remission (CR) who received IT and systemic chemotherapy without RT, compared with 555 healthy controls [<a href="#rid95">95</a>]. ALL/LBL survivors had a six- to eight-point decrease in IQ test scores and moderate impairments in working memory, information processing speed, and fine motor functioning. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mental health</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A meta-analysis reported that while most pediatric ALL/LBL survivors are well adjusted, there is an increase in anxiety and depression [<a href="#rid100">100</a>]. Adult survivors of childhood cancer are at an increased risk for both suicidal ideation and symptoms of post-traumatic stress disorder (PTSD) compared with healthy controls [<a href="#rid100">100</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A study of 2208 survivors and 10,457 controls reported that survivors of adolescent and young adult cancer had an increased rate of mental health visits (relative risk [RR] 1.3 [95% CI 1.1-1.5]) and increased risk for a severe psychologic event (ie, suicide, emergency department visit, admission; hazard ratio [HR] 2.0 [95% CI 1.3-2.4]) [<a href="#rid101">101,102</a>]. </p><p></p><p class="headingAnchor" id="H10"><span class="h3">Stroke</span><span class="headingEndMark"> — </span>Survivors of childhood leukemia are at an increased risk for late-occurring stroke. </p><p>The Childhood Cancer Survivor Study (CCSS) reported that, compared with their siblings, children who survived childhood leukemia for ≥5 years had an increased risk for stroke (RR 6.4 [95% CI 3-13.8]) [<a href="#rid103">103</a>]. Compared with age-matched siblings, patients who received &gt;30 Gy cranial RT were more likely to have late-occurring stroke; however, the stroke risk was not elevated for patients who received chemotherapy only or RT ≤30 Gy.</p><p class="headingAnchor" id="H11"><span class="h3">Other neurologic sequelae</span><span class="headingEndMark"> — </span>Adult survivors of childhood leukemia are at risk for late-onset auditory-vestibular-visual sensory deficits, coordination and motor problems, seizures, and headaches [<a href="#rid104">104</a>]. These neurologic findings were more likely to occur in patients who relapsed or had received intracranial RT. Subtle behavioral and educational sequelae may also be noted in survivors of childhood ALL/LBL [<a href="#rid105">105,106</a>].</p><p class="headingAnchor" id="H2081859057"><span class="h2">Endocrinopathies</span><span class="headingEndMark"> — </span>Endocrine dysfunction, including thyroid disorders, obesity, diabetes mellitus, and gonadal dysfunction, are among the most common late treatment-related AEs after childhood ALL/LBL. The cumulative risk steadily increases over time and is more common in those who received high-dose RT to the head, neck, or pelvis, or after exposure to high doses of alkylating agents. </p><p>In a study of 14,290 childhood cancer survivors with a median follow-up of 25 years, 46 percent of childhood leukemia survivors exhibited endocrine dysfunction, including hypo- or hyperthyroidism, thyroid cancer, growth hormone deficiency, obesity, and diabetes mellitus [<a href="#rid77">77</a>]. (See  <a class="medical medical_review" href="/z/d/html/93313.html" rel="external">"Endocrinopathies in cancer survivors and others exposed to cytotoxic therapies during childhood"</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Impaired growth</span><span class="headingEndMark"> — </span>Many children with ALL/LBL experience "catch-up" growth after completion of chemotherapy, but some have permanent short stature. The cause of short stature may be multifactorial, as no single aspect of treatment has been implicated. </p><p>A study from the CCSS reported shorter adult height for 2434 ALL/LBL survivors compared with 3009 of their siblings [<a href="#rid107">107</a>]. Across all treatments, ALL/LBL survivors had decreased adult height and increased risk of adult short stature (ie, height standard deviation scores less than -2; overall risk [OR] 12.5 [95% CI 8.1-19.2]). Those treated with chemotherapy only had a higher risk of adult short stature compared with their siblings (OR 3.4 [95% CI 1.9-6]); no specific chemotherapy agent was implicated. Risk factors for short stature included diagnosis of ALL/LBL before puberty, higher-dose cranial RT (≥20 Gy versus &lt;20 Gy), RT to the spine, and female sex.</p><p>Some patients have low growth hormone (GH) levels due to abnormal hypothalamic-pituitary function from cranial RT [<a href="#rid80">80,107,108</a>]. However, GH levels at the end of treatment do not correlate with adult height for children treated with regimens that did not include cranial RT [<a href="#rid109">109</a>]. Other patients may have undiagnosed mild, primary, or central hypothyroidism. Childhood ALL/LBL survivors are also at an increased risk for developing osteoporosis, which can result in vertebral compression fractures and loss of height [<a href="#rid80">80,110,111</a>]. </p><p>Further discussion of growth failure and bone problems in childhood cancer survivors is presented separately. (See  <a class="medical medical_review" href="/z/d/html/5830.html" rel="external">"Bone problems in childhood cancer patients", section on 'Reduced bone mineral density'</a> and  <a class="medical medical_review" href="/z/d/html/93313.html" rel="external">"Endocrinopathies in cancer survivors and others exposed to cytotoxic therapies during childhood", section on 'Disordered growth'</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Obesity</span><span class="headingEndMark"> — </span>The incidence of obesity is increased in long-term survivors of childhood ALL/LBL. Cranial RT is associated with obesity, but other risk factors are less well defined.</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of 47 studies, which included data from 1742 childhood ALL/LBL survivors, reported an increased incidence in obesity in all patient subgroups, regardless of sex, age at diagnosis, or history of cranial RT [<a href="#rid112">112</a>]. The mean body mass index (BMI) Z-score was 0.83, which corresponds to the 80<sup>th</sup> BMI percentile and is higher than that in a healthy population (expected mean BMI Z-score between 0.4 and 0.6). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another meta-analysis reported an age- and race-adjusted increased risk for obesity (BMI &gt;30 kg/m<sup>2</sup>) in survivors treated with cranial RT ≥20 Gy [<a href="#rid113">113</a>]. This is a higher RT dose than most current pediatric treatment regimens, and it is uncertain if current RT doses will be associated with obesity. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A prospective study of 456 children who were treated using a single protocol reported that the prevalence of obesity in the 248 ALL/LBL survivors who attained adult height was comparable to that of the general population [<a href="#rid114">114</a>]. Risk factors for obesity in ALL/LBL survivors included a young age (&lt;6 years) and being overweight or obese at the time of diagnosis. There was no effect of RT or RT dose on the rate of obesity. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study from the CCSS reported that adiposity, insulin resistance, dyslipidemia, and higher leptin levels were increased in 273 young adults who received cranial RT [<a href="#rid115">115</a>]. However, in another study, increased BMI was associated with higher levels of corticosteroid exposure but not exposure to cranial RT, according to multivariate analysis [<a href="#rid116">116</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obese survivors of childhood ALL/LBL had a greater risk of relapse compared with those who are not obese, according to data from the Children's Cancer Group (1995 to 1998) [<a href="#rid117">117</a>]. Compared with 3971 nonobese survivors, 343 obese survivors had a lower five-year event-free survival (EFS; 72 versus 77 percent; HR 1.36 [95% CI 1.04-1.77]) and higher risk of relapse (26 versus 20 percent; HR 1.29 [95% CI 1.02-1.56]). These effects were more prominent in 1003 patients ≥10 years old at diagnosis and were confirmed with a separate cohort of 1160 survivors. </p><p></p><p class="bulletIndent1">Other studies also reported an increased incidence of obesity and other cardiovascular risk factors [<a href="#rid113">113,115,116,118-121</a>]. </p><p></p><p class="headingAnchor" id="H19"><span class="h3">Glucose metabolism</span><span class="headingEndMark"> — </span>Abnormal glucose metabolism may occur during induction therapy and can persist after treatment is complete.</p><p>Glucose metabolism and pancreatic beta cell function may be affected during treatment of ALL/LBL by L-asparaginase, <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a>, or the leukemic process [<a href="#rid122">122,123</a>]. Abnormal glucose metabolism may persist after completion of therapy in some patients [<a href="#rid124">124</a>]. Among 32 children with ALL/LBL who were off of therapy for ≥1 year, 22 had an impaired insulin response, 9 had impaired glucose tolerance, and 1 had overt diabetes [<a href="#rid119">119,125</a>]. </p><p>In a retrospective analysis of 91 survivors of childhood ALL/LBL or non-Hodgkin lymphoma, the prevalence of insulin resistance was higher among those who underwent allogeneic hematopoietic cell transplantation/total body irradiation (88 percent), compared with patients who were not transplanted and received either chemotherapy only (9 percent) or chemotherapy plus cranial RT (16 percent) [<a href="#rid126">126</a>]. A retrospective study of 167 children with ALL/LBL reported that hyperglycemia during induction was associated with increased rates of mortality and relapse [<a href="#rid127">127</a>]; however, these findings await confirmation in other studies, and it is uncertain if glycemic control would improve these outcomes.</p><p class="headingAnchor" id="H20"><span class="h3">Reproductive health</span><span class="headingEndMark"> — </span>Reproductive capacity and sexual function of ALL/LBL survivors are affected by age at the time of treatment and by the components of therapy. </p><p>Postpubescent males with ALL/LBL can have treatment-related declines in reproductive function, particularly after treatment with high-dose alkylating agents [<a href="#rid83">83</a>], while gonadal function and fertility of prepubescent ALL/LBL patients are relatively unaffected [<a href="#rid128">128</a>].</p><p>Both males and females are more likely to have decreased fertility if treated with high-dose (≥24 Gy) cranial RT [<a href="#rid129">129</a>]. Females are more likely to have decreased fertility if they received cranial RT around the time of menarche [<a href="#rid129">129</a>] and are at risk for premature ovarian insufficiency [<a href="#rid77">77</a>].</p><p>Congenital abnormalities are no more common among the offspring of ALL/LBL survivors than the general population [<a href="#rid129">129,130</a>].</p><p class="headingAnchor" id="H3196873740"><span class="h3">Thyroid dysfunction</span><span class="headingEndMark"> — </span>Survivors of childhood ALL/LBL are at an increased risk of thyroid disorders, including underactive or overactive thyroid, thyroid nodules, and thyroid cancers [<a href="#rid77">77</a>]. The risk is greatest for those who underwent RT, but the risk is increased at least twofold even in patients who did not receive RT or high-dose alkylator therapy.</p><p class="headingAnchor" id="H1696890486"><span class="h2">Cardiotoxicity</span><span class="headingEndMark"> — </span>Cardiovascular disease is more common in survivors of childhood ALL/LBL.</p><p>One study reported that cardiovascular disease by age 45 years was at least fivefold higher among 3466 childhood cancer survivors compared with their siblings without cancer [<a href="#rid81">81</a>]. Treatment with anthracyclines (eg, <a class="drug drug_pediatric" data-topicid="13207" href="/z/d/drug information/13207.html" rel="external">daunorubicin</a>, <a class="drug drug_pediatric" data-topicid="13254" href="/z/d/drug information/13254.html" rel="external">doxorubicin</a>) may cause cardiovascular complications, including irreversible and fatal cardiomyopathy [<a href="#rid131">131</a>]. However, doses of anthracyclines used in current regimens and/or the use of <a class="drug drug_pediatric" data-topicid="13216" href="/z/d/drug information/13216.html" rel="external">dexrazoxane</a> as a cardioprotectant are associated with less cardiotoxicity [<a href="#rid132">132,133</a>].</p><p>Management of anthracycline cardiotoxicity and monitoring children for acute and late manifestations of cardiotoxicity are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a> and  <a class="medical medical_review" href="/z/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity"</a>.)</p><p class="headingAnchor" id="H2478873759"><span class="h2">Infections</span><span class="headingEndMark"> — </span>Infections are a frequent complication after treatment for ALL/LBL. </p><p>In a retrospective, single-institution study, 2204 childhood leukemia survivors were matched with 11,020 age-matched controls [<a href="#rid134">134</a>]. Compared with controls, the rate of infections in leukemia survivors was elevated 1.8-fold at &lt;1 year, 1.7-fold between one to five years, and 1.3-fold ≥5 years after the completion of treatment. As a registry study, it was not possible to correlate infectious events with specific risk factors (eg, central venous lines or graft-versus-host disease), and it is uncertain if contemporary treatment protocols are associated with such risks for infections.</p><p>Survivors of ALL/LBL were more likely than their siblings to have health care visits related to infections and disorders of the immune system [<a href="#rid81">81</a>]</p><p class="headingAnchor" id="H3646136262"><span class="h2">Second neoplasms</span><span class="headingEndMark"> — </span>Approximately 2 to 3 percent of childhood ALL/LBL survivors develop a second malignancy [<a href="#rid75">75,135-137</a>]. </p><p>Brain tumors and hematologic malignancies (eg, acute myeloid leukemia [AML]) are the most common secondary malignancies [<a href="#rid135">135,138,139</a>]. The risk of a second cancer is greatest among patients who received cranial RT [<a href="#rid128">128,138</a>] or intensive therapy for relapse [<a href="#rid140">140</a>]. </p><p>Among 856 survivors of ALL/LBL with &gt;10 years EFS, 44 developed second malignancies, 41 of which were radiation related [<a href="#rid68">68</a>]. The estimated rates for a second malignancy 30 years after remission induction were 20.9 and 0.95 percent for those receiving RT or not receiving RT, respectively. Virtually all tumors in children who received RT arose in the field of irradiation, and most were either benign or low grade; the most common tumors were basal cell carcinomas (10), meningiomas (10), malignant brain tumors (5), and thyroid carcinoma (4). It is unclear if patients receiving current doses of prophylactic radiation (eg, 12 Gy) will have similar rates of secondary neoplasms. </p><p class="headingAnchor" id="H229891673"><span class="h3">Brain tumors</span><span class="headingEndMark"> — </span>In a review of almost 10,000 children treated for ALL/LBL, the risk of developing a primary brain tumor, particularly an astrocytoma, was increased 22-fold, which corresponds to a 1 to 2 percent cumulative incidence over 10 to 20 years [<a href="#rid141">141</a>]. Brain tumors were seen only in children who had previously undergone cranial RT. Similar findings were noted in another series of children with ALL/LBL [<a href="#rid142">142</a>]. Children treated with cranial RT for ALL/LBL may also develop glioblastoma multiforme; in one series of 37 such children, three experienced multifocal tumors [<a href="#rid143">143</a>].</p><p>The combination of prophylactic cranial RT with orally administered <a class="drug drug_pediatric" data-topicid="12582" href="/z/d/drug information/12582.html" rel="external">6-mercaptopurine</a> (6MP) was associated with a higher-than-expected incidence of brain tumors in survivors of ALL/LBL who have genetic defects in 6MP metabolism [<a href="#rid142">142</a>].</p><p>Adult survivors of childhood ALL/LBL who received cranial RT are also at high risk of developing subsequent meningiomas. With a median follow-up of 25 years, 22 percent of 49 adult survivors who received cranial RT developed meningiomas; no other brain tumors were reported [<a href="#rid144">144</a>]. Meningiomas occurred only in patients who received cranial RT doses ≥21 Gy. The incidence of meningioma was higher in patients treated by 1980 (47 percent), but it is uncertain if this is related to longer follow-up or to higher RT doses (eg, 21 to 25 Gy). </p><p class="headingAnchor" id="H3889281909"><span class="h3">Hematologic malignancies</span><span class="headingEndMark"> — </span>Survivors of childhood ALL/LBL are at risk for the development of a secondary hematologic malignancy. </p><p>A retrospective review of 2169 children with ALL/LBL treated at a single institution (1962 to 1998) reported secondary myeloid malignancies in 2.2 percent [<a href="#rid145">145</a>]. Most cases were AML, but there were also cases of myelodysplastic syndrome/neoplasms and chronic myeloid leukemia. The median follow-up was &gt;18 years, and compared with the United States general population, the standardized incident ratio was 150.9 (95% CI 98.1-185.4).</p><p class="headingAnchor" id="H21"><span class="h1">LONG-TERM FOLLOW-UP</span><span class="headingEndMark"> — </span>ALL/LBL survivors should have comprehensive follow-up care, with attention to nutritional assessments, education, growth monitoring, mental health and social functioning, and education to prevent high-risk behaviors. </p><p>Ideally, care should transition to either a clinic dedicated to childhood cancer long-term survivors or to a clinician (eg, pediatrician, family practice, or internal medicine) who has an association or contact with a long-term survivor clinic, if questions arise. For high-risk groups (eg, those who have received craniospinal, testicular, or other radiation therapy), additional follow-up and imaging may be necessary. </p><p>The nature and schedule of screening for secondary malignancies is influenced by the treatment received. Since the risk of malignancy recurrence is highest during the period immediately following the completion of chemotherapy, an intensive follow-up schedule is often specified as part of protocols. </p><p>Specific long-term follow-up guidelines after treatment of childhood cancer have been published by the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.survivorshipguidelines.org%2F&amp;token=S16MTPPY6cpS0A68kxrRsQOkLnEIm8%2BQaMhQyNKCcl%2BJTIC9BC9aNpypysLPfb9F&amp;TOPIC_ID=6247" target="_blank">Children's Oncology Group</a>. Those undergoing hematopoietic stem cell transplantation have risks for additional long-term complications.</p><p class="headingAnchor" id="H9939525"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83252.html" rel="external">"Patient education: Leukemia in children (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) is the most common cancer in children. Advances in treatment are associated with improved outcomes, with long-term overall survival and event-free survival that approach 90 percent in many settings. (See <a class="local">'Outcomes'</a> above.)</p><p></p><p class="bulletIndent1">Children with ALL/LBL in the setting of Down syndrome/trisomy 21 or various inherited conditions may require distinctive treatment, experience specific toxicities, and have different prognoses compared with ALL/LBL in children with these underlying conditions. Outcomes and adverse effects with treatment are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2917.html" rel="external">"Down syndrome: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/93183.html" rel="external">"Familial disorders of acute leukemia and myelodysplastic syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – Features associated with outcomes of treatment for ALL/LBL include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Age</strong> – Outcomes are less favorable for infants and adolescents/young adults. (See <a class="local">'Effect of age'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Leukemia classification</strong> – Outcomes vary with the leukemic subtype:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>B cell ALL/LBL </strong>– This is generally the most favorable category, but outcomes vary with clinical and pathologic features. (See <a class="local">'B cell ALL/LBL'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>T cell ALL/LBL</strong> – Risk-stratified treatment has led to outcomes that approach those with B cell disease. (See <a class="local">'T cell ALL/LBL'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Philadelphia chromosome-positive/</strong><strong><em>BCR::ABL1</em></strong><strong> ALL/LBL</strong> – This category was traditionally associated with an adverse prognosis, but treatment that includes a tyrosine kinase inhibitor has greatly improved outcomes. (See <a class="local">'Philadelphia chromosome positive/BCR::ABL1 positive'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Philadelphia chromosome-like ALL/LBL</strong> – This diverse category remains a challenging clinical problem, with newer approaches informed by molecular features. (See <a class="local">'Philadelphia chromosome-like ALL/LBL'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical/genetic features</strong> – Children with hypodiploid karyotype, certain mutations, and slow response to induction therapy are associated with inferior outcomes. (See <a class="local">'Outcomes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Late effects of treatment</strong> – Long-term complications of treatment are related to the type and intensity of treatment. (See <a class="local">'Late effects'</a> above.)</p><p></p><p class="bulletIndent1">Late effects include: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neurologic</strong> – Impaired cognition, stroke, and neurodevelopmental delay. (See <a class="local">'Neurologic effects'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endocrine</strong> – Growth retardation, obesity, abnormal glucose metabolism, reduced fertility, and thyroid dysfunction. (See <a class="local">'Endocrinopathies'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiac</strong> – Cardiomyopathy. (See <a class="local">'Cardiotoxicity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infections</strong>. (See <a class="local">'Infections'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Second cancers</strong> – Other hematologic malignancies, brain tumors, and other cancers. (See <a class="local">'Second neoplasms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance of long-term follow-up</strong> – Survivors of childhood ALL/LBL must continue long-term oncology follow-up to detect and manage long-term complications. (See <a class="local">'Long-term follow-up'</a> above.)</p><p></p><p><strong>ACKNOWLEDGMENT</strong> — The UpToDate editorial staff acknowledges C Philip Steuber, MD, who contributed to earlier versions of this topic.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Trigg ME, Sather HN, Reaman GH, et al. Ten-year survival of children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leuk Lymphoma 2008; 49:1142.</a></li><li><a class="nounderline abstract_t">Pulte D, Gondos A, Brenner H. Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004. J Natl Cancer Inst 2008; 100:1301.</a></li><li><a class="nounderline abstract_t">Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol 2012; 30:1663.</a></li><li><a class="nounderline abstract_t">Ma H, Sun H, Sun X. Survival improvement by decade of patients aged 0-14 years with acute lymphoblastic leukemia: a SEER analysis. Sci Rep 2014; 4:4227.</a></li><li><a class="nounderline abstract_t">Raetz EA, Bhojwani D, Devidas M, et al. Children's Oncology Group blueprint for research: Acute lymphoblastic leukemia. Pediatr Blood Cancer 2023; 70 Suppl 6:e30585.</a></li><li><a class="nounderline abstract_t">Hunger SP, Loh ML, Whitlock JA, et al. Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer 2013; 60:957.</a></li><li><a class="nounderline abstract_t">Schrappe M, Möricke A, Reiter A, et al. Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000. Klin Padiatr 2013; 225 Suppl 1:S62.</a></li><li><a class="nounderline abstract_t">Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int 2018; 60:4.</a></li><li><a class="nounderline abstract_t">Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med 2015; 373:1541.</a></li><li><a class="nounderline abstract_t">Nandakumar A, Anantha N, Venugopal T, et al. Descriptive epidemiology of lymphoid and haemopoietic malignancies in Bangalore, India. Int J Cancer 1995; 63:37.</a></li><li><a class="nounderline abstract_t">Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015; 385:977.</a></li><li><a class="nounderline abstract_t">Metzger ML, Howard SC, Fu LC, et al. Outcome of childhood acute lymphoblastic leukaemia in resource-poor countries. Lancet 2003; 362:706.</a></li><li><a class="nounderline abstract_t">Howard SC, Pedrosa M, Lins M, et al. Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA 2004; 291:2471.</a></li><li><a class="nounderline abstract_t">Lee JW, Cho B. Prognostic factors and treatment of pediatric acute lymphoblastic leukemia. Korean J Pediatr 2017; 60:129.</a></li><li><a class="nounderline abstract_t">Stary J, Zimmermann M, Campbell M, et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol 2014; 32:174.</a></li><li><a class="nounderline abstract_t">Rivera GK, Ribeiro RC. Improving treatment of children with acute lymphoblastic leukemia in developing countries through technology sharing, collaboration and partnerships. Expert Rev Hematol 2014; 7:649.</a></li><li><a class="nounderline abstract_t">Roberts KG. Genetics and prognosis of ALL in children vs adults. Hematology Am Soc Hematol Educ Program 2018; 2018:137.</a></li><li><a class="nounderline abstract_t">Pui CH, Kane JR, Crist WM. Biology and treatment of infant leukemias. Leukemia 1995; 9:762.</a></li><li><a class="nounderline abstract_t">Chessells JM, Eden OB, Bailey CC, et al. Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL trials. Report from the Medical Research Council Working Party on Childhood Leukaemia. Leukemia 1994; 8:1275.</a></li><li><a class="nounderline abstract_t">Dreyer ZE, Hilden JM, Jones TL, et al. Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3). Pediatr Blood Cancer 2015; 62:419.</a></li><li><a class="nounderline abstract_t">Roberts I, Fordham NJ, Rao A, Bain BJ. Neonatal leukaemia. Br J Haematol 2018; 182:170.</a></li><li><a class="nounderline abstract_t">Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007; 370:240.</a></li><li><a class="nounderline abstract_t">Frankel LS, Ochs J, Shuster JJ, et al. Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). J Pediatr Hematol Oncol 1997; 19:35.</a></li><li><a class="nounderline abstract_t">Marco F, Bureo E, Ortega JJ, et al. High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support. Groupo Español de Trasplante de Médula Osea en Niños. J Clin Oncol 2000; 18:3256.</a></li><li><a class="nounderline abstract_t">Chessells JM, Harrison CJ, Kempski H, et al. Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party. Leukemia 2002; 16:776.</a></li><li><a class="nounderline abstract_t">Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359:1909.</a></li><li><a class="nounderline abstract_t">Isoyama K, Eguchi M, Hibi S, et al. Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status: results of the Japan Infant Leukaemia Study (MLL96). Br J Haematol 2002; 118:999.</a></li><li><a class="nounderline abstract_t">Brown PA. Neonatal Leukemia. Clin Perinatol 2021; 48:15.</a></li><li><a class="nounderline abstract_t">Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022; 140:1200.</a></li><li><a class="nounderline abstract_t">Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36:1720.</a></li><li><a class="nounderline abstract_t">Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica 2020; 105:2524.</a></li><li><a class="nounderline abstract_t">Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet 2020; 395:1146.</a></li><li><a class="nounderline abstract_t">Inaba H, Pui CH. Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia. J Clin Med 2021; 10.</a></li><li><a class="nounderline abstract_t">Lange BJ, Bostrom BC, Cherlow JM, et al. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2002; 99:825.</a></li><li><a class="nounderline abstract_t">Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia 2000; 14:2205.</a></li><li><a class="nounderline abstract_t">LeClerc JM, Billett AL, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01. J Clin Oncol 2002; 20:237.</a></li><li><a class="nounderline abstract_t">Kamps WA, Veerman AJ, van Wering ER, et al. Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991. Leukemia 2000; 14:2240.</a></li><li><a class="nounderline abstract_t">Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97:1211.</a></li><li><a class="nounderline abstract_t">Millot F, Suciu S, Philippe N, et al. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. J Clin Oncol 2001; 19:1935.</a></li><li><a class="nounderline abstract_t">Matloub Y, Bostrom BC, Hunger SP, et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011; 118:243.</a></li><li><a class="nounderline abstract_t">Mattano LA Jr, Devidas M, Maloney KW, et al. Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. J Clin Oncol 2021; 39:1540.</a></li><li><a class="nounderline abstract_t">Larsen EC, Devidas M, Chen S, et al. Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. J Clin Oncol 2016; 34:2380.</a></li><li><a class="nounderline abstract_t">Aricò M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342:998.</a></li><li><a class="nounderline abstract_t">Hann I, Vora A, Harrison G, et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol 2001; 113:103.</a></li><li><a class="nounderline abstract_t">Visser JH, Wessels G, Hesseling PB, et al. Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2001; 18:187.</a></li><li><a class="nounderline abstract_t">Safavi S, Paulsson K. Near-haploid and low-hypodiploid acute lymphoblastic leukemia: two distinct subtypes with consistently poor prognosis. Blood 2017; 129:420.</a></li><li><a class="nounderline abstract_t">McNeer JL, Devidas M, Dai Y, et al. Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. J Clin Oncol 2019; 37:780.</a></li><li><a class="nounderline abstract_t">Pui CH, Yang JJ, Hunger SP, et al. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol 2015; 33:2938.</a></li><li><a class="nounderline abstract_t">Borowitz MJ, Wood BL, Devidas M, et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. Blood 2015; 126:964.</a></li><li><a class="nounderline abstract_t">Teachey DT, Pui CH. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol 2019; 20:e142.</a></li><li><a class="nounderline abstract_t">Cordo' V, van der Zwet JCG, Canté-Barrett K, et al. T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies. Blood Cancer Discov 2021; 2:19.</a></li><li><a class="nounderline abstract_t">Uckun FM, Sensel MG, Sun L, et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 1998; 91:735.</a></li><li><a class="nounderline abstract_t">Steinherz PG, Gaynon PS, Breneman JC, et al. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group. Cancer 1998; 82:600.</a></li><li><a class="nounderline abstract_t">Winter SS, Dunsmore KP, Devidas M, et al. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. J Clin Oncol 2018; 36:2926.</a></li><li><a class="nounderline abstract_t">Dunsmore KP, Winter SS, Devidas M, et al. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol 2020; 38:3282.</a></li><li><a class="nounderline abstract_t">Slayton WB, Schultz KR, Silverman LB, Hunger SP. How we approach Philadelphia chromosome-positive acute lymphoblastic leukemia in children and young adults. Pediatr Blood Cancer 2020; 67:e28543.</a></li><li><a class="nounderline abstract_t">Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia 2014; 28:1467.</a></li><li><a class="nounderline abstract_t">Slayton WB, Schultz KR, Kairalla JA, et al. Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. J Clin Oncol 2018; 36:2306.</a></li><li><a class="nounderline abstract_t">Shen S, Chen X, Cai J, et al. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA Oncol 2020; 6:358.</a></li><li><a class="nounderline abstract_t">Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360:470.</a></li><li><a class="nounderline abstract_t">Harvey RC, Mullighan CG, Wang X, et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 2010; 116:4874.</a></li><li><a class="nounderline abstract_t">Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014; 371:1005.</a></li><li><a class="nounderline abstract_t">Sherali N, Hamadneh T, Aftab S, et al. Integration of Next-Generation Sequencing in Diagnosing and Minimal Residual Disease Detection in Patients With Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia. Cureus 2020; 12:e10696.</a></li><li><a class="nounderline abstract_t">Pui CH, Roberts KG, Yang JJ, Mullighan CG. Philadelphia Chromosome-like Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 2017; 17:464.</a></li><li><a class="nounderline abstract_t">Gaynon PS, Qu RP, Chappell RJ, et al. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse--the Children's Cancer Group Experience. Cancer 1998; 82:1387.</a></li><li><a class="nounderline abstract_t">Chessells JM, Leiper AD, Tiedemann K, et al. Oral methotrexate is as effective as intramuscular in maintenance therapy of acute lymphoblastic leukaemia. Arch Dis Child 1987; 62:172.</a></li><li><a class="nounderline abstract_t">George SL, Aur RJ, Mauer AM, Simone JV. A reappraisal of the results of stopping therapy in childhood leukemia. N Engl J Med 1979; 300:269.</a></li><li><a class="nounderline abstract_t">Pui CH, Cheng C, Leung W, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med 2003; 349:640.</a></li><li><a class="nounderline abstract_t">Teachey DT, Hunger SP. Predicting relapse risk in childhood acute lymphoblastic leukaemia. Br J Haematol 2013; 162:606.</a></li><li><a class="nounderline abstract_t">Conter V, Aricò M, Valsecchi MG, et al. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica. Haematologica 1998; 83:791.</a></li><li><a class="nounderline abstract_t">Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000; 95:3310.</a></li><li><a class="nounderline abstract_t">Pui CH, Boyett JM, Rivera GK, et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000; 14:2286.</a></li><li><a class="nounderline abstract_t">Christensen MS, Heyman M, Möttönen M, et al. Treatment-related death in childhood acute lymphoblastic leukaemia in the Nordic countries: 1992-2001. Br J Haematol 2005; 131:50.</a></li><li><a class="nounderline abstract_t">Mertens AC, Yong J, Dietz AC, et al. Conditional survival in pediatric malignancies: analysis of data from the Childhood Cancer Survivor Study and the Surveillance, Epidemiology, and End Results Program. Cancer 2015; 121:1108.</a></li><li><a class="nounderline abstract_t">Armstrong GT, Chen Y, Yasui Y, et al. Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. N Engl J Med 2016; 374:833.</a></li><li><a class="nounderline abstract_t">Robison LL, Bhatia S. Late-effects among survivors of leukaemia and lymphoma during childhood and adolescence. Br J Haematol 2003; 122:345.</a></li><li><a class="nounderline abstract_t">Mostoufi-Moab S, Seidel K, Leisenring WM, et al. Endocrine Abnormalities in Aging Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol 2016; 34:3240.</a></li><li><a class="nounderline abstract_t">Hudson MM, Mertens AC, Yasui Y, et al. Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JAMA 2003; 290:1583.</a></li><li><a class="nounderline abstract_t">Meeske KA, Siegel SE, Globe DR, et al. Prevalence and correlates of fatigue in long-term survivors of childhood leukemia. J Clin Oncol 2005; 23:5501.</a></li><li><a class="nounderline abstract_t">Essig S, Li Q, Chen Y, et al. Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol 2014; 15:841.</a></li><li><a class="nounderline abstract_t">Chang WH, Katsoulis M, Tan YY, et al. Late effects of cancer in children, teenagers and young adults: Population-based study on the burden of 183 conditions, in-patient and critical care admissions and years of life lost. Lancet Reg Health Eur 2022; 12:100248.</a></li><li><a class="nounderline abstract_t">Moore IM, Espy KA, Kaufmann P, et al. Cognitive consequences and central nervous system injury following treatment for childhood leukemia. Semin Oncol Nurs 2000; 16:279.</a></li><li><a class="nounderline abstract_t">Ise T, Kishi K, Imashuku S, et al. Testicular histology and function following long-term chemotherapy of acute leukemia in children and outcome of the patients who received testicular biopsy. Am J Pediatr Hematol Oncol 1986; 8:288.</a></li><li><a class="nounderline abstract_t">Krull KR, Bhojwani D, Conklin HM, et al. Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 2013; 31:2182.</a></li><li><a class="nounderline abstract_t">Krull KR, Hardy KK, Kahalley LS, et al. Neurocognitive Outcomes and Interventions in Long-Term Survivors of Childhood Cancer. J Clin Oncol 2018; 36:2181.</a></li><li><a class="nounderline abstract_t">von der Weid N, Swiss Pediatric Oncology Group (SPOG). Late effects in long-term survivors of ALL in childhood: experiences from the SPOG late effects study. Swiss Med Wkly 2001; 131:180.</a></li><li><a class="nounderline abstract_t">Paolucci G, Vecchi V, Favre C, et al. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study. Haematologica 2001; 86:478.</a></li><li><a class="nounderline abstract_t">Krull KR, Zhang N, Santucci A, et al. Long-term decline in intelligence among adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiation. Blood 2013; 122:550.</a></li><li><a class="nounderline abstract_t">Schuitema I, Deprez S, Van Hecke W, et al. Accelerated aging, decreased white matter integrity, and associated neuropsychological dysfunction 25 years after pediatric lymphoid malignancies. J Clin Oncol 2013; 31:3378.</a></li><li><a class="nounderline abstract_t">Krull KR, Brinkman TM, Li C, et al. Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study. J Clin Oncol 2013; 31:4407.</a></li><li><a class="nounderline abstract_t">Waber DP, Shapiro BL, Carpentieri SC, et al. Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01. Cancer 2001; 92:15.</a></li><li><a class="nounderline abstract_t">von der Weid N, Mosimann I, Hirt A, et al. Intellectual outcome in children and adolescents with acute lymphoblastic leukaemia treated with chemotherapy alone: age- and sex-related differences. Eur J Cancer 2003; 39:359.</a></li><li><a class="nounderline abstract_t">Jansen NC, Kingma A, Schuitema A, et al. Post-treatment intellectual functioning in children treated for acute lymphoblastic leukaemia (ALL) with chemotherapy-only: a prospective, sibling-controlled study. Eur J Cancer 2006; 42:2765.</a></li><li><a class="nounderline abstract_t">Conklin HM, Krull KR, Reddick WE, et al. Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia. J Natl Cancer Inst 2012; 104:1386.</a></li><li><a class="nounderline abstract_t">Iyer NS, Balsamo LM, Bracken MB, Kadan-Lottick NS. Chemotherapy-only treatment effects on long-term neurocognitive functioning in childhood ALL survivors: a review and meta-analysis. Blood 2015; 126:346.</a></li><li><a class="nounderline abstract_t">Jacola LM, Krull KR, Pui CH, et al. Longitudinal Assessment of Neurocognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia Treated on a Contemporary Chemotherapy Protocol. J Clin Oncol 2016; 34:1239.</a></li><li><a class="nounderline abstract_t">Iuvone L, Mariotti P, Colosimo C, et al. Long-term cognitive outcome, brain computed tomography scan, and magnetic resonance imaging in children cured for acute lymphoblastic leukemia. Cancer 2002; 95:2562.</a></li><li><a class="nounderline abstract_t">Zając-Spychała O, Pawlak MA, Karmelita-Katulska K, et al. Long-term brain structural magnetic resonance imaging and cognitive functioning in children treated for acute lymphoblastic leukemia with high-dose methotrexate chemotherapy alone or combined with CNS radiotherapy at reduced total dose to 12 Gy. Neuroradiology 2017; 59:147.</a></li><li><a class="nounderline abstract_t">Harila-Saari AH, Lähteenmäki PM, Pukkala E, et al. Scholastic achievements of childhood leukemia patients: a nationwide, register-based study. J Clin Oncol 2007; 25:3518.</a></li><li><a class="nounderline abstract_t">Brinkman TM, Recklitis CJ, Michel G, et al. Psychological Symptoms, Social Outcomes, Socioeconomic Attainment, and Health Behaviors Among Survivors of Childhood Cancer: Current State of the Literature. J Clin Oncol 2018; 36:2190.</a></li><li><a class="nounderline abstract_t">De R, Sutradhar R, Kurdyak P, et al. Incidence and Predictors of Mental Health Outcomes Among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study Using the IMPACT Cohort. J Clin Oncol 2021; 39:1010.</a></li><li><a class="nounderline abstract_t">Nathan PC, Nachman A, Sutradhar R, et al. Adverse mental health outcomes in a population-based cohort of survivors of childhood cancer. Cancer 2018; 124:2045.</a></li><li><a class="nounderline abstract_t">Bowers DC, Liu Y, Leisenring W, et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2006; 24:5277.</a></li><li><a class="nounderline abstract_t">Goldsby RE, Liu Q, Nathan PC, et al. Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2010; 28:324.</a></li><li><a class="nounderline abstract_t">Buizer AI, de Sonneville LM, van den Heuvel-Eibrink MM, Veerman AJ. Behavioral and educational limitations after chemotherapy for childhood acute lymphoblastic leukemia or Wilms tumor. Cancer 2006; 106:2067.</a></li><li><a class="nounderline abstract_t">Zeller B, Tamnes CK, Kanellopoulos A, et al. Reduced neuroanatomic volumes in long-term survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 2013; 31:2078.</a></li><li><a class="nounderline abstract_t">Chow EJ, Friedman DL, Yasui Y, et al. Decreased adult height in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Pediatr 2007; 150:370.</a></li><li><a class="nounderline abstract_t">Stubberfield TG, Byrne GC, Jones TW. Growth and growth hormone secretion after treatment for acute lymphoblastic leukemia in childhood. 18-Gy versus 24-Gy cranial irradiation. J Pediatr Hematol Oncol 1995; 17:167.</a></li><li><a class="nounderline abstract_t">Vandecruys E, Dhooge C, Craen M, et al. Longitudinal linear growth and final height is impaired in childhood acute lymphoblastic leukemia survivors after treatment without cranial irradiation. J Pediatr 2013; 163:268.</a></li><li><a class="nounderline abstract_t">Alos N, Grant RM, Ramsay T, et al. High incidence of vertebral fractures in children with acute lymphoblastic leukemia 12 months after the initiation of therapy. J Clin Oncol 2012; 30:2760.</a></li><li><a class="nounderline abstract_t">Wilson CL, Chemaitilly W, Jones KE, et al. Modifiable Factors Associated With Aging Phenotypes Among Adult Survivors of Childhood Acute Lymphoblastic Leukemia. J Clin Oncol 2016; 34:2509.</a></li><li><a class="nounderline abstract_t">Zhang FF, Kelly MJ, Saltzman E, et al. Obesity in pediatric ALL survivors: a meta-analysis. Pediatrics 2014; 133:e704.</a></li><li><a class="nounderline abstract_t">Oeffinger KC, Mertens AC, Sklar CA, et al. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2003; 21:1359.</a></li><li><a class="nounderline abstract_t">Razzouk BI, Rose SR, Hongeng S, et al. Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma. J Clin Oncol 2007; 25:1183.</a></li><li><a class="nounderline abstract_t">Ross JA, Oeffinger KC, Davies SM, et al. Genetic variation in the leptin receptor gene and obesity in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2004; 22:3558.</a></li><li><a class="nounderline abstract_t">Janiszewski PM, Oeffinger KC, Church TS, et al. Abdominal obesity, liver fat, and muscle composition in survivors of childhood acute lymphoblastic leukemia. J Clin Endocrinol Metab 2007; 92:3816.</a></li><li><a class="nounderline abstract_t">Butturini AM, Dorey FJ, Lange BJ, et al. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol 2007; 25:2063.</a></li><li><a class="nounderline abstract_t">Oeffinger KC, Buchanan GR, Eshelman DA, et al. Cardiovascular risk factors in young adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2001; 23:424.</a></li><li><a class="nounderline abstract_t">Warner JT, Evans WD, Webb DK, Gregory JW. Body composition of long-term survivors of acute lymphoblastic leukaemia. Med Pediatr Oncol 2002; 38:165.</a></li><li><a class="nounderline abstract_t">Chow EJ, Pihoker C, Hunt K, et al. Obesity and hypertension among children after treatment for acute lymphoblastic leukemia. Cancer 2007; 110:2313.</a></li><li><a class="nounderline abstract_t">Ness KK, DeLany JP, Kaste SC, et al. Energy balance and fitness in adult survivors of childhood acute lymphoblastic leukemia. Blood 2015; 125:3411.</a></li><li><a class="nounderline abstract_t">Pastore G, Saracco P, Brach del Prever A, et al. Glucose metabolism in children with acute lymphoblastic leukemia treated according to two different L-asparaginase schedules. Acta Haematol 1984; 72:384.</a></li><li><a class="nounderline abstract_t">Dacou-Voutetakis C, Palis J, Haidas S, et al. Abnormal glucose tolerance in children with acute leukemia. Effect of induction chemotherapy including L-asparaginase. Am J Pediatr Hematol Oncol 1983; 5:139.</a></li><li><a class="nounderline abstract_t">Oudin C, Simeoni MC, Sirvent N, et al. Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia. Blood 2011; 117:4442.</a></li><li><a class="nounderline abstract_t">Mohn A, Di Marzio A, Capanna R, et al. Persistence of impaired pancreatic beta-cell function in children treated for acute lymphoblastic leukaemia. Lancet 2004; 363:127.</a></li><li><a class="nounderline abstract_t">Beauloye V, Steffens M, Zech F, et al. Characterization of insulin resistance in young adult survivors of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma. Clin Endocrinol (Oxf) 2013; 78:790.</a></li><li><a class="nounderline abstract_t">Sonabend RY, McKay SV, Okcu MF, et al. Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia. J Pediatr 2009; 155:73.</a></li><li><a class="nounderline abstract_t">Kadan-Lottick N, Neglia JP. Pediatric acute lymphoblastic leukemia: redefining outcomes. J Pediatr Hematol Oncol 2002; 24:88.</a></li><li><a class="nounderline abstract_t">Byrne J, Fears TR, Mills JL, et al. Fertility in women treated with cranial radiotherapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2004; 42:589.</a></li><li><a class="nounderline abstract_t">Nygaard R, Clausen N, Siimes MA, et al. Reproduction following treatment for childhood leukemia: a population-based prospective cohort study of fertility and offspring. Med Pediatr Oncol 1991; 19:459.</a></li><li><a class="nounderline abstract_t">Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339:900.</a></li><li><a class="nounderline abstract_t">Bertorello N, Luksch R, Bisogno G, et al. Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane. Pediatr Blood Cancer 2023; :e30515.</a></li><li><a class="nounderline abstract_t">Chow EJ, Aggarwal S, Doody DR, et al. Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer. J Clin Oncol 2023; 41:2248.</a></li><li><a class="nounderline abstract_t">Pelland-Marcotte MC, Pole JD, Hwee J, et al. Long-Term Risk of Infections After Treatment of Childhood Leukemia: A Population-Based Cohort Study Using Administrative Health Data. J Clin Oncol 2019; 37:2651.</a></li><li><a class="nounderline abstract_t">Kimball Dalton VM, Gelber RD, Li F, et al. Second malignancies in patients treated for childhood acute lymphoblastic leukemia. J Clin Oncol 1998; 16:2848.</a></li><li><a class="nounderline abstract_t">Maule M, Scélo G, Pastore G, et al. Risk of second malignant neoplasms after childhood leukemia and lymphoma: an international study. J Natl Cancer Inst 2007; 99:790.</a></li><li><a class="nounderline abstract_t">Ishida Y, Maeda M, Urayama KY, et al. Secondary cancers among children with acute lymphoblastic leukaemia treated by the Tokyo Children's Cancer Study Group protocols: a retrospective cohort study. Br J Haematol 2014; 164:101.</a></li><li><a class="nounderline abstract_t">Löning L, Zimmermann M, Reiter A, et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 2000; 95:2770.</a></li><li><a class="nounderline abstract_t">Schmiegelow K, Levinsen MF, Attarbaschi A, et al. Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 2013; 31:2469.</a></li><li><a class="nounderline abstract_t">Borgmann A, Zinn C, Hartmann R, et al. Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. Eur J Cancer 2008; 44:257.</a></li><li><a class="nounderline abstract_t">Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 325:1330.</a></li><li><a class="nounderline abstract_t">Relling MV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999; 354:34.</a></li><li><a class="nounderline abstract_t">Fontana M, Stanton C, Pompili A, et al. Late multifocal gliomas in adolescents previously treated for acute lymphoblastic leukemia. Cancer 1987; 60:1510.</a></li><li><a class="nounderline abstract_t">Banerjee J, Pääkkö E, Harila M, et al. Radiation-induced meningiomas: a shadow in the success story of childhood leukemia. Neuro Oncol 2009; 11:543.</a></li><li><a class="nounderline abstract_t">Hijiya N, Hudson MM, Lensing S, et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 2007; 297:1207.</a></li></ol></div><div id="topicVersionRevision">Topic 6247 Version 54.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18569638" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Ten-year survival of children with acute lymphoblastic leukemia: a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18780868" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22412151" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24572378" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Survival improvement by decade of patients aged 0-14 years with acute lymphoblastic leukemia: a SEER analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37489549" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Children's Oncology Group blueprint for research: Acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23255467" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23700060" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29143423" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Treatment and biology of pediatric acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26465987" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Acute Lymphoblastic Leukemia in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7558449" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Descriptive epidemiology of lymphoid and haemopoietic malignancies in Bangalore, India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25467588" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12957095" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Outcome of childhood acute lymphoblastic leukaemia in resource-poor countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15161898" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28592975" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prognostic factors and treatment of pediatric acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24344215" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25174644" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Improving treatment of children with acute lymphoblastic leukemia in developing countries through technology sharing, collaboration and partnerships.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30504302" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Genetics and prognosis of ALL in children vs adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7769837" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Biology and treatment of infant leukemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8057661" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL trials. Report from the Medical Research Council Working Party on Childhood Leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25399948" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29806701" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Neonatal leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17658395" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9065717" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10986058" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support. Groupo Español de Trasplante de Médula Osea en Niños.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11986937" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12057554" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12199778" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status: results of the Japan Infant Leukaemia Study (MLL96).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33583502" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Neonatal Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35767897" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732829" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33054110" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pediatric acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32247396" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Acute lymphoblastic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33946897" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11806983" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11187912" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11773175" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11187915" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11222362" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11283125" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21562038" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33739852" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27114587" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10749961" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11328289" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11293286" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27903530" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Near-haploid and low-hypodiploid acute lymphoblastic leukemia: two distinct subtypes with consistently poor prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30742559" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26304874" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26124497" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30842058" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34661151" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9446631" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Biology and treatment of childhood T-lineage acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9452280" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30138085" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32813610" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32779849" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : How we approach Philadelphia chromosome-positive acute lymphoblastic leukemia in children and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24441288" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29812996" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31944221" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19129520" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20699438" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25207766" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33133861" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Integration of Next-Generation Sequencing in Diagnosing and Minimal Residual Disease Detection in Patients With Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28842136" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Philadelphia Chromosome-like Acute Lymphoblastic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9529033" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse--the Children's Cancer Group Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3469936" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Oral methotrexate is as effective as intramuscular in maintenance therapy of acute lymphoblastic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/282457" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A reappraisal of the results of stopping therapy in childhood leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12917300" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23808872" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Predicting relapse risk in childhood acute lymphoblastic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9825576" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10828010" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11187920" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16173962" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Treatment-related death in childhood acute lymphoblastic leukaemia in the Nordic countries: 1992-2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25557134" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Conditional survival in pediatric malignancies: analysis of data from the Childhood Cancer Survivor Study and the Surveillance, Epidemiology, and End Results Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26761625" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12877662" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Late-effects among survivors of leukaemia and lymphoma during childhood and adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27382091" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Endocrine Abnormalities in Aging Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14506117" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16110010" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Prevalence and correlates of fatigue in long-term survivors of childhood leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24954778" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34950917" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Late effects of cancer in children, teenagers and young adults: Population-based study on the burden of 183 conditions, in-patient and critical care admissions and years of life lost.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11109272" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Cognitive consequences and central nervous system injury following treatment for childhood leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3467601" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Testicular histology and function following long-term chemotherapy of acute leukemia in children and outcome of the patients who received testicular biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23650422" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29874137" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Neurocognitive Outcomes and Interventions in Long-Term Survivors of Childhood Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11345808" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Late effects in long-term survivors of ALL in childhood: experiences from the SPOG late effects study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11410410" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23744583" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Long-term decline in intelligence among adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23960182" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Accelerated aging, decreased white matter integrity, and associated neuropsychological dysfunction 25 years after pediatric lymphoid malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24190124" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11443604" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12565989" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Intellectual outcome in children and adolescents with acute lymphoblastic leukaemia treated with chemotherapy alone: age- and sex-related differences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16935489" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Post-treatment intellectual functioning in children treated for acute lymphoblastic leukaemia (ALL) with chemotherapy-only: a prospective, sibling-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22927505" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26048910" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Chemotherapy-only treatment effects on long-term neurocognitive functioning in childhood ALL survivors: a review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26858334" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Longitudinal Assessment of Neurocognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia Treated on a Contemporary Chemotherapy Protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12467071" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Long-term cognitive outcome, brain computed tomography scan, and magnetic resonance imaging in children cured for acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28074235" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Long-term brain structural magnetic resonance imaging and cognitive functioning in children treated for acute lymphoblastic leukemia with high-dose methotrexate chemotherapy alone or combined with CNS radiotherapy at reduced total dose to 12 Gy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17687156" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Scholastic achievements of childhood leukemia patients: a nationwide, register-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29874134" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Psychological Symptoms, Social Outcomes, Socioeconomic Attainment, and Health Behaviors Among Survivors of Childhood Cancer: Current State of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33492982" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Incidence and Predictors of Mental Health Outcomes Among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study Using the IMPACT Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29468664" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Adverse mental health outcomes in a population-based cohort of survivors of childhood cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17088567" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19917844" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16568441" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Behavioral and educational limitations after chemotherapy for childhood acute lymphoblastic leukemia or Wilms tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23589559" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Reduced neuroanatomic volumes in long-term survivors of childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17382112" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Decreased adult height in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7749768" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Growth and growth hormone secretion after treatment for acute lymphoblastic leukemia in childhood. 18-Gy versus 24-Gy cranial irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23351599" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Longitudinal linear growth and final height is impaired in childhood acute lymphoblastic leukemia survivors after treatment without cranial irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22734031" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : High incidence of vertebral fractures in children with acute lymphoblastic leukemia 12 months after the initiation of therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27001572" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Modifiable Factors Associated With Aging Phenotypes Among Adult Survivors of Childhood Acute Lymphoblastic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24534408" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Obesity in pediatric ALL survivors: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12663727" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17401007" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15337805" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Genetic variation in the leptin receptor gene and obesity in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17652222" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Abdominal obesity, liver fat, and muscle composition in survivors of childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17513811" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Obesity and outcome in pediatric acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11878576" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Cardiovascular risk factors in young adult survivors of childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11836715" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Body composition of long-term survivors of acute lymphoblastic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17896787" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Obesity and hypertension among children after treatment for acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25814529" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Energy balance and fitness in adult survivors of childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6442522" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Glucose metabolism in children with acute lymphoblastic leukemia treated according to two different L-asparaginase schedules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6351658" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Abnormal glucose tolerance in children with acute leukemia. Effect of induction chemotherapy including L-asparaginase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21278355" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14726167" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Persistence of impaired pancreatic beta-cell function in children treated for acute lymphoblastic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22967316" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Characterization of insulin resistance in young adult survivors of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19394046" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11990711" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Pediatric acute lymphoblastic leukemia: redefining outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15127413" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Fertility in women treated with cranial radiotherapy for childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1961132" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Reproduction following treatment for childhood leukemia: a population-based prospective cohort study of fertility and offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9744975" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Doxorubicin-induced cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37355856" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36669148" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31393747" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Long-Term Risk of Infections After Treatment of Childhood Leukemia: A Population-Based Cohort Study Using Administrative Health Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9704738" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Second malignancies in patients treated for childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17505074" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Risk of second malignant neoplasms after childhood leukemia and lymphoma: an international study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24116892" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Secondary cancers among children with acute lymphoblastic leukaemia treated by the Tokyo Children's Cancer Study Group protocols: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10779419" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23690411" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17981026" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1922234" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Second neoplasms after acute lymphoblastic leukemia in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10406363" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : High incidence of secondary brain tumours after radiotherapy and antimetabolites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3476182" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Late multifocal gliomas in adolescents previously treated for acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19179425" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Radiation-induced meningiomas: a shadow in the success story of childhood leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17374815" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
